Monica Limardo

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors.

Zbigniew Pietrzkowski, Reiner Lammers, G Carpenter et al. · PubMed · 1992 · 161 citations

Human Growth, Immunology, Cell Proliferation +16

Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study

Gabriella Moroni, Andrea Doria, Elisa Giglio et al. · Journal of Autoimmunity · 2016 · 120 citations

Glomerulonephritis, Urology, Autoimmune Disease +11

Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study

Monica Limardo, E Imbasciati, Pietro Ravani et al. · American Journal of Kidney Diseases · 2010 · 65 citations

Glomerulonephritis, Urology, Medicine +12